ONCOLYTICS BIOTECH INC 10-K — AI Bull & Bear Analysis

The 10-K reveals a high-stakes binary outcome for Oncolytics Biotech. On one side, the company has a scientifically validated platform with strong signals in GI oncology and a clear regulatory roadmap. On the other, it is fighting a battle against a dwindling cash runway and a depressed share price. The successful domestication to Nevada and the appointment of a new executive team are clear signals that the company is seeking an exit via partnership or acquisition rather than attempting to build a fully independent commercial entity. Ultimately, the investment thesis hinges on whether the upcoming preliminary data from the mCRC and SCAC programs can trigger a strategic transaction before the company exhausts its remaining capital. The tension between the 'transformative' clinical narrative and the 'distressed' financial reality defines the current risk-reward profile for shareholders.